The Prescribers’ Dilemma: Treatment of Hepatitis C Infection for Medicaid Insured Patients in United States
Journal Title: Liver Research – Open Journal - Year 2015, Vol 1, Issue 2
Abstract
Introduction of Direct Acting Antivirals (DAA) to Hepatitis C Virus (HCV) treatment armamentarium has offered a great boost to the providers’ confidence to safely and effectively treat HCV infection in the majority of patients. However, the cost of these medications is high and thus access is poor. Medicaid insurance providers have devised stringent eligibility criteria to approve the cost of DAA for its members. We reviewed the criteria among various Medicaid agencies from States of Ohio and Pennsylvania and noticed similarities and differences among them. The prerequisite process demanding clinical, laboratory, radiologic or histologic documentation is quite cumbersome and sometimes confusing. In certain aspects the eligibility requirements for DAA are not in concordance with the clinical evidence provided by the recently updated guidelines. We have addressed the dilemma most of the providers face while planning HCV treatment for the Medicaid insured patients in regards to the needed testing, clinical documentation and liver fibrosis assessment, along with the clinical implications of such requirements. While HCV remains a major public health issue, variable State Medicaid policies may lead to disparity in access to the emerging DAA with subsequent healthcare outcomes. These gaps may compromise long term efforts of the public health HCV initiatives.
Authors and Affiliations
Hicham Khallafi
Keywords
Related Articles
- EP ID EP556622
- DOI 10.17140/LROJ-1-105
- Views 144
- Downloads 0
“Cardiac Hepatopathy”: A Review of Liver Dysfunction in Heart Failure
The unique dual circulation of the liver confers relative protection against ischemic injury; however, low oxygen tension in the microcirculation (sinusoidal blood of the hepatic acinus) may render hepatocytes in zone 3...
Acute Liver Injury during Co-treatment with Levetiracetam and Temozolomide
Drug-induced liver injury (DILI) accounts for approximately 10 percent of all cases of acute hepatitis. The patterns of acute injury include any form of hepatic injury, but the most common problems are cholestasis, hepat...
The Prescribers’ Dilemma: Treatment of Hepatitis C Infection for Medicaid Insured Patients in United States
Introduction of Direct Acting Antivirals (DAA) to Hepatitis C Virus (HCV) treatment armamentarium has offered a great boost to the providers’ confidence to safely and effectively treat HCV infection in the majority of pa...
Cardiovascular Disease and NASH
Non-alcoholic fatty liver disease (NAFLD) and Non-alcoholic steatohepatitis (NASH) are associated with cardiovascular events and Metabolic Syndrome (MetS). NAFLD is considered to be a hepatic manifestation of MetS and ha...
Metastatic Liver Disease - Presenting as Multiple Hepatic Cysts
A 59 year-old woman with a history of successfully treated Hepatitis-C, Systemic Lupus Erythematosus, and a remote history of melanoma of the scalp presented to our center for evaluation of abdominal pain, nausea, vomiti...